GPT and interstitial lung disease: The results indicated that although the median PFS (8.9 months (95% CI: 3.9–11.1)) and OS (26.3 months (95% CI: 20.0–31.0)) in the cohort that received abemaciclib plus pembrolizumab were higher compared to the MONARCH 1 [118] and KEYNOTE-028 [119] studies, the incidence of interstitial lung disease/pneumonia (grade ≥ 3 ILD/pneumonitis = 7.7%) and severe transaminase elevations (grade ≥ 3 ALT increased = 42.3%, grade ≥ 3 AST increased = 34.6%) was high regardless of whether anastrozole was used.